Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -2418.8%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $76M | $122M | $62M | $42M | — | — | — | — | — | — | — |
| Enterprise Value | $72M | $118M | $71M | $36M | — | — | — | — | — | — | — |
| P/E Ratio → | -1.55 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 37.44 | 74.50 | — | 3.71 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 95.6% | 36.9% | 23.6% | 90.6% | 51.8% | 49.7% |
| Operating Margin | — | — | — | — | — | -138.8% | -1919.2% | -2595.2% | -356.0% | -6.0% | -5.7% |
| Net Profit Margin | — | — | — | — | — | -93.2% | -2781.5% | -2734.2% | -497.0% | 9.6% | 4.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2418.8% | -2418.8% | -170157.4% | -347.0% | -62.4% | -32.4% | — | -25020.3% | -171.4% | 14.5% | 7.3% |
| ROA | -146.5% | -146.5% | -187.6% | -141.3% | -47.3% | -36.7% | -270.5% | -211.1% | -106.3% | 5.7% | 2.8% |
| ROIC | — | — | -2692.7% | -383.1% | -592.1% | — | — | — | -1910.8% | -3.7% | -3.8% |
| ROCE | -219.2% | -219.2% | -264.3% | -215.4% | -47.0% | -313.0% | — | -1683.7% | -98.3% | -4.0% | -4.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.87 | 8.87 | — | 0.61 | 0.84 | 0.06 | — | — | — | 1.19 | 1.28 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 85.13 | 123.65 |
| Net Debt / Equity | — | -2.48 | — | -0.53 | -0.04 | -1.03 | — | — | -1.35 | 0.73 | 0.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 52.24 | 91.73 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 1.74 | 3.97 |
| Interest Coverage | -33.29 | -33.29 | -113.06 | -32.23 | -6.84 | -60.16 | -8.06 | — | — | 6.77 | 4.88 |
Net cash position: cash ($19M) exceeds total debt ($15M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.38 | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 | 0.38 | 0.23 | 3.49 | 2.28 | 1.87 |
| Quick Ratio | 2.38 | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 | 0.38 | 0.23 | 3.49 | 2.28 | 1.87 |
| Cash Ratio | 2.29 | 2.29 | 1.53 | 1.32 | 1.14 | 7.86 | 0.32 | 0.21 | 3.47 | 1.79 | 1.27 |
| Asset Turnover | — | — | — | — | — | 0.29 | 0.06 | 0.13 | 0.15 | 0.59 | 0.66 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 10.39 | 633.68 | 108.00 | 9.69 | 26.94 | 29.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.4% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.4% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $15M | $12M | $5M | $3M | $3M | $8M | $8M | $3M | $6120 | $6120 |
Imminent liquidity and dilution
According to recent market data, ELTX trades at a price-to-book ratio of 37.44, a figure that reflects the market's pricing of intangible clinical potential rather than tangible assets, as the company lacks meaningful revenue or earnings to support traditional valuation multiples like P/E or P/S.
The absence of positive earnings or sales renders standard valuation metrics largely irrelevant for assessing the company's intrinsic value. Investors appear to be pricing the stock based on the probability-weighted success of the AMP platform, which implies that any delay in clinical milestones could lead to a significant contraction in the current valuation multiple.
As reported in financial statements, ELTX's ROIC has fluctuated significantly, reaching -128.1% in 2023Q4, which underscores the company's current inability to generate returns on invested capital while it remains in the intensive, cash-consuming phase of clinical development for its lead oncology candidates.
The persistent negative return on capital is a structural characteristic of a pre-revenue biotechnology firm where capital is deployed into R&D rather than income-generating assets. This trend suggests that shareholders should not expect positive capital efficiency until the company successfully transitions to a commercial or licensing model.
Based on the company's reported figures, the current ratio has trended downward to 2.24 as of 2026Q1, indicating that while the firm maintains a basic level of short-term solvency, its liquidity position is rapidly eroding under the weight of ongoing clinical trial expenditures.
The reliance on cash reserves to fund operations without offsetting revenue streams creates a precarious liquidity profile that leaves little room for clinical setbacks. Investors should monitor the current ratio closely, as any further decline may signal an urgent need for external capital to maintain operational continuity.
As indicated by comparative market data, ELTX's valuation and financial profile differ significantly from peers like Immunocore, where the latter's more advanced clinical stage and potential partnership revenue create a distinct risk-reward profile compared to Elicio's current early-stage, high-burn operational status.
The gap between ELTX and its peers is structural, driven by the company's lack of a major pharmaceutical partnership to offset development costs. This suggests that the company's valuation may remain disconnected from broader sector trends until it can demonstrate a similar level of clinical validation or strategic backing.
The price-to-book ratio is frequently misapplied to ELTX, as it obscures the reality that the company's true value resides in its intellectual property and clinical data rather than the accounting value of its physical assets, which are negligible in the context of its R&D-heavy business model.
Investors should instead focus on cash runway and clinical milestone progress, as the book value is heavily distorted by accumulated deficits and reverse merger accounting. Relying on P/B as a valuation anchor may lead to a false sense of security regarding the company's underlying financial health.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELTX stock.
Elicio Therapeutics, Inc.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Elicio Therapeutics, Inc.'s return on equity (ROE) is -2418.8%. The historical average is -98.6%.
Based on historical data, Elicio Therapeutics, Inc. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.